Abstract: The invention provides 19-substituted geldanamycin derivatives, and pharmaceutically acceptable salts thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer or neurodegenerative disorders.

Abstract: The present invention relates to methods of isolating and purifying sulforaphane. More specifically, the present invention relates to methods of isolating and purifying sulforaphane from natural sources. The present invention also relates to methods of forming high purity complexes of sulforaphane with cyclodextrin.

Abstract: The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue.

Abstract: A pharmaceutical composition for improving wound healing is provided. The pharmaceutical composition includes (a) hyaluronic acid or its derivation, (b) an effective amount of an active ingredient; and optionally (c) pharmaceutically acceptable carriers and/or excipients. In one embodiment, the active ingredient includes vitamin. In another embodiment, the active ingredient includes acexamic acid. In still another embodiment, the pharmaceutical composition can further comprise sorbic acid.

Abstract: Processes for precipitating a polymer from a polymer-containing fluid are disclosed, which include providing a vessel housing a medium that provides one or more precipitation surfaces. A polymer-containing fluid, e.g., a polymer solution, dispersion or mixed solution/dispersion, and an anti-solvent can be introduced into the vessel so as to cause precipitation of at least a portion of the polymer on at least one of the precipitation surfaces. In some embodiments, the polymer contains one or more cyclic oligosaccharide moieties, such as one or more cyclodextrin moieties (e.g., ?-cyclodextrin, ?-cyclodextrin, and ?-cyclodextrin). The polymer can be any of a linear or branched polymer. The polymer can be any of polycation, a polyanion, or a non-ionic polymer. Also disclosed herein are precipitation surfaces with polymer precipitated thereon.

Abstract: To provide a chiral reagent or a salt thereof. The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (—NO2), a halogen atom, a cyano group (—CN), a group of formula (II) or (III), or both G1 and G2 taken together to form a group of formula (IV).

Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

Abstract: This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety.

Abstract: The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (I); a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.

Abstract: Combustion reactions release pollutant gases that associate with ocular fluids and tissues which can have an acute ocular impact. The chronic irritation and chemical effects of these gases also promote ocular aging over the lifespan. Instantaneous pollutant effects can be reduced at the time of eye exposure by using an eyewash (collyrium) composition comprising hydroxocobalamin and/or hydroxo(aquo)cobalamin. Such compositions minimize pollutant gas reactions with ocular tissues by (1) deactivating the gases; and (2) expediting their removal from the eye by, for example, aqueous rinsing and dilution.

Abstract: The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of Huntington's disease.

Abstract: The present invention relates to a method of synthesizing sulforaphane by reacting a compound of formula (A) with an oxidizing agent in an aqueous solvent and in the presence of a catalyst. The invention further provides a method of synthesizing a stabilized complex of sulforaphane and cyclodextrin by mixing the sulforaphane prepared by the methodology defined herein with cyclodextrin in an aqueous solvent.

Abstract: The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.

Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.

Abstract: The invention concerns a pentasaccharide compound of formula (I) and the salts thereof. The invention also concerns a pharmaceutical composition comprising the synthetic pentasaccharide compound of formula (I) and its salts. The invention further concerns these compounds for use as a medicament, and in particular intended to treat blood clotting disorders, to prevent ischaemia reperfusion injury associated with solid organ transplantation, or to reduce the risk of blood clotting in an extracorporeal blood circuit during cardiac surgery, extracorporeal membrane oxygenation, or during circulatory assistance such as artificial heart.

Abstract: The present disclosure provides an A3 adenosine receptor (A3AR) ligand for the treatment of sexual dysfunction. In some embodiments the A3AR ligand is selected from an A3AR agonist and A3AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A3 adenosine receptor (A3AR) ligand. In some embodiments, the A3AR ligand is an A3AR agonist and more specifically, IB-MECA.

Abstract: A method and composition for treating chronic inflammatory disorders comprising a pharmaceutically acceptable carrier suitable for oral administration or injection and containing a therapeutic amount of a complex of dietary supplement ingredients comprising nicotinamide, quercetin, curcumin, EPA, DHA, hesperetin and glychrrhizin.

Abstract: The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient.

Abstract: The invention features protected linker compounds which comprise at one terminus a protected amino group and at another other terminus a phosphorous activating group, such as a phosphoramidite group. These protected linker compounds are introduced chemically at the 5?-end of oligonucleotides for the purpose of preparing 5?-amino modified oligonucleotides. After deprotection, the thereby introduced amino group then allows further modification (e.g. attachment of dyes) or immobilization (on surfaces or beads) of the oligonucleotide. Specifically, the presented amino protecting group is designed to provide such protected linker compounds in a solid form, which facilitates efficient purification by precipitation or crystallization and aliquoting for distribution and storage.

Abstract: The present invention relates to a method for the preparation of chitosan of a degree of acetylation DAr, from chitosan ? having a degree of acetylation DAi lower than DAr, comprising at least one step of purification and at least one step of acetylation of said chitosan ?, said purification step comprising at least one step of solubilization of said chitosan ? in an acidic aqueous medium and at least one step of precipitation of said thus solubilized chitosan, wherein said acetylation step is carried out in a solution on said solubilized chitosan before said precipitation step.